Inositol does help with insulin resistance, and the evidence is strongest for two forms: myo-inositol and d-chiro-inositol. A large meta-analysis of randomized controlled trials found that inositol supplementation reduced HOMA-IR (a standard measure of insulin resistance) by an average of 1.21 points and lowered fasting insulin by about 4.74 µU/mL compared to controls. The benefits are most pronounced in people who already have a metabolic condition like PCOS, type 2 diabetes, obesity, or metabolic syndrome.
How Inositol Improves Insulin Sensitivity
Inositol works as a second messenger in your body’s insulin signaling chain. When insulin binds to a cell receptor, it triggers the release of small molecules called inositol phosphoglycans. These molecules carry out two key jobs: they help your cells pull glucose out of the bloodstream by increasing the number of glucose transporters (GLUT-4) on cell surfaces, and they boost your cells’ ability to store that glucose as glycogen for energy.
Myo-inositol and d-chiro-inositol handle slightly different parts of this process. Myo-inositol primarily supports the signaling pathway that moves glucose into cells. D-chiro-inositol activates an enzyme that feeds glucose into your cells’ main energy-producing cycle, improving how efficiently your body burns sugar for fuel. Together, they enhance both glucose uptake and glucose metabolism, which is why supplements often combine them.
Evidence in PCOS
Polycystic ovary syndrome is where inositol has been studied most extensively, since insulin resistance drives many of PCOS’s hormonal disruptions. A meta-analysis of randomized controlled trials found that myo-inositol significantly reduced both fasting insulin and HOMA-IR scores in women with PCOS compared to controls. These improvements in insulin sensitivity also led to downstream hormonal changes: lower testosterone, lower LH-to-FSH ratio, and better ovulation rates.
In one 12-week trial, 2 grams of myo-inositol per day led to significant reductions in plasma insulin, testosterone, and prolactin in overweight women with PCOS, along with measurable improvements in insulin sensitivity. Head-to-head comparisons with metformin, the most commonly prescribed drug for insulin resistance, show that myo-inositol produces comparable metabolic and hormonal benefits with generally better tolerability. Metformin may still have an edge in cases of severe insulin resistance, but for many women with PCOS, inositol achieves similar results with fewer gastrointestinal side effects.
Benefits Beyond PCOS
Inositol’s effects on insulin resistance aren’t limited to PCOS. People with obesity, metabolic syndrome, non-alcoholic fatty liver disease, and type 2 diabetes also show significant improvements. In subgroup analyses, these populations saw fasting glucose drop by an average of 12.66 mg/dL, fasting insulin fall by 3.70 µU/mL, and HOMA-IR decrease by 1.66 points. By contrast, healthy participants without a metabolic condition did not see meaningful changes in insulin or glucose levels, suggesting inositol corrects an existing problem rather than pushing already-normal metabolism further.
In a study of 80 postmenopausal women with metabolic syndrome, 2 grams per day of myo-inositol improved blood glucose, insulin, HOMA-IR, triglycerides, total and HDL cholesterol, and blood pressure compared to placebo. That’s a broad metabolic benefit from a single supplement. One limitation: the evidence for reducing HbA1c (a marker of long-term blood sugar control) is not yet statistically significant, so the strongest effects appear to be on fasting insulin and short-term glucose handling rather than three-month blood sugar averages.
Gestational Diabetes Prevention
For pregnant women at high risk of gestational diabetes, inositol shows real promise. In a randomized controlled trial of 200 women, those who took 4,000 mg of myo-inositol daily from early pregnancy through 26 to 28 weeks had a gestational diabetes rate of 14.9%, compared to 28.5% in the control group. That’s roughly cutting the risk in half. The supplemented group also had significantly lower glucose values on oral glucose tolerance testing, lower HOMA-IR scores, and higher insulin sensitivity. Other trials have reported even larger reductions in gestational diabetes incidence, ranging from 65% to 87%.
Dosage and the 40:1 Ratio
The most commonly used dose in clinical trials is 2 grams of myo-inositol twice daily (4 grams total per day), often paired with folic acid. This is the dose that has shown consistent results across PCOS, metabolic syndrome, and gestational diabetes studies. For d-chiro-inositol alone, trials have used 1,200 mg per day, which in one study reduced insulin levels after a glucose challenge by 62% in obese women with PCOS over eight weeks.
Many supplements now combine myo-inositol and d-chiro-inositol in a 40:1 ratio, which mirrors the natural ratio of these two forms in human blood plasma. The rationale is that insulin resistance can disrupt the body’s normal conversion of myo-inositol to d-chiro-inositol, so providing both in their physiological proportion helps restore balance. Clinical data supports this approach. In women with the most severe PCOS phenotype, the 40:1 combination significantly reduced HOMA-IR, fasting insulin, and BMI. Different tissues have different ratios (ovarian tissue, for example, has a 100:1 ratio favoring myo-inositol), which is part of why the combined formula may work better than d-chiro-inositol alone, particularly for reproductive outcomes.
Safety and Side Effects
Inositol has a strong safety profile. At the doses used in clinical trials (2 to 4 grams per day), side effects are minimal. Even at 12 grams per day, which is three to six times the typical supplemental dose, the only reported side effects were mild gastrointestinal symptoms like nausea, gas, and loose stools. These effects did not become more severe at higher doses. This tolerability is one of inositol’s practical advantages over metformin, which commonly causes nausea, diarrhea, and stomach cramping that lead some people to stop taking it.
Most clinical trials have run 8 to 24 weeks, so the long-term data is more limited. But given that inositol is a naturally occurring compound found in foods like beans, citrus fruits, and whole grains, and that it’s produced by the body itself, the risk profile at standard doses is low. Results in clinical trials typically begin appearing within 8 to 12 weeks of consistent use.